Nonetheless, the circumvention of EMT-associated resistance to ALK–TKIs to restore the sensitivity of mesenchymal-type tumor cells to ALK–TKIs, remains an unmet need of targeted drug therapy in ALK-rearranged NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.